A Study to Assess the Safety, Tolerability, and Efficacy of ST-400 for Treatment of Transfusion-Dependent Beta-thalassemia (TDT)
a study on Beta Thalassemia
Summary
- Eligibility
- for people ages 18-40 (full criteria)
- Location
- at Oakland, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- Mark Walters, M.D.
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Mark Walters, M.D.
The over-arching goal of my research career has been to develop and expand curative therapies for hemoglobin disorders in particular and non-malignant hematopoietic disorders more broadly. I have focused on genome editing approaches most recently, which rely upon modification of autologous hematopoietic cells to elicit a curative effect.
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Sangamo Therapeutics
- ID
- NCT03432364
- Phase
- Phase 1/2
- Study Type
- Interventional
- Last Updated